Carisol

Quick links to important sections

Carisol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carisol

Property Description
Active ingredient Carisoprodol
Form Tablet (Oral formulation)
Pharmacological class Centrally Acting Skeletal Muscle Relaxant (CASMR), Carbamate derivative
General purpose Relief from acute muscle spasm
Origin Synthetic

Carisol: A Centrally Acting Skeletal Muscle Relaxant

Carisol is the trade name for the synthetic medicine with the official non-proprietary name (INN) Carisoprodol, which is chemically defined as a carbamate derivative. This drug belongs to the pharmacological class of Centrally Acting Skeletal Muscle Relaxants (CASMRs), meaning its therapeutic action is primarily exerted within the central nervous system (CNS), which includes the brain and spinal cord. This single-ingredient medicine is designed exclusively for oral formulation and is consistently supplied as a tablet, a distinguishing factor when compared to forms requiring localized application.

The classification as a CASMR is clinically recognized for its role in providing relief from the discomfort and mobility restrictions caused by acute muscle spasm associated with musculoskeletal conditions. Carisoprodol acts centrally to produce skeletal muscle relaxation. The drug’s mechanism aims to chemically reduce the nervous system activity that sustains the painful cycle of muscle rigidity and tension, which is particularly helpful in managing short-term stiffness.

Composition, Origin, and General Purpose

The sole active ingredient in Carisol is Carisoprodol. This synthetic compound possesses a unique chemical nature as a prodrug because it undergoes metabolism within the body, resulting in the creation of a separate, active substance called Meprobamate. This metabolic process means that both Carisoprodol and its metabolite contribute to the drug's high-level mechanism: generalized CNS depression.

This central action serves the drug's general therapeutic purpose of easing involuntary stiffness and rigidity in the skeletal muscles. The medication, often positioned for short-term use only, is a synthetic product specifically designed to modulate central nerve signals to achieve muscle relaxation. This characteristic of converting to Meprobamate is a key differentiator from other non-carbamate relaxants.

Regulatory References

  1. Source: NIH MedlinePlus Carisoprodol Summary

What side effects are possible with Carisol?

Carisol is a central nervous system (CNS) depressant. The drug is classified as a Schedule IV controlled substance due to its potential for abuse, dependence, and withdrawal, which have been reported with prolonged use. Because of these risks, the duration of treatment is typically limited to two or three weeks.

Adverse Reactions

The most common adverse reactions reported in clinical trials (incidence greater than 2%) are related to CNS effects:

Adverse Reaction Incidence (Most Common)
Drowsiness Common
Dizziness Common
Headache Common

Postmarketing experience has identified additional adverse reactions across several system-organ classes, including:**

  • Serious CNS Effects: Seizures (reported primarily in the setting of overdose or use with other drugs of abuse potential), vertigo, ataxia, agitation, irritability, and depressive reactions.
  • Gastrointestinal: Nausea, vomiting, and epigastric discomfort.
  • Cardiovascular: Tachycardia (fast heart rate) and postural hypotension (a drop in blood pressure when standing).

Safety Considerations

Carisol is generally not recommended for use in older adults (65 years and over), as it may not be as safe or effective as alternative treatments in this population. It is contraindicated in patients with a history of acute intermittent Porphyria or a known hypersensitivity to the drug or related compounds (carbamates).

The sedative effects of Carisol are additive with other CNS depressants, including alcohol, which can significantly impair mental and physical abilities needed to perform hazardous tasks, such as driving or operating machinery. Caution is also advised when the drug is used in patients with a history of drug abuse, liver disease, kidney disease, or a pre-existing seizure disorder.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Carisoprodol is primarily characterized by profound Central Nervous System (CNS) depression, which is the core documented toxicity according to regulatory information. The severity of overdose is markedly increased when Carisol is taken in combination with alcohol or other CNS depressants; this combination constitutes a high-risk factor associated with reported seizures and fatalities.

Documented Overdose Manifestations Severe Outcomes and Life-Threatening Risks
Confusion, nystagmus, blurred vision, muscular incoordination, rigidity, hypotension, and mild tachycardia. Coma, severe respiratory depression, seizures, shock, and death.

Immediate medical attention must be sought, or a Poison Control Center contacted, upon any suspected overdose. Basic life support measures must be initiated as dictated by clinical presentation.

Treatment is strictly symptomatic and supportive. This includes maintaining vital functions through circulatory support and possibly gastric lavage. Regulatory guidance notes that induced vomiting is not recommended due to the risk of exacerbating CNS depression. No specific antidote is officially documented for Carisoprodol overdose.

Therapeutic Uses of Carisol

What Carisol Treats: Main Uses and Benefits

Carisol is commonly used for the symptomatic relief of acute, painful musculoskeletal conditions. The medication is considered relevant for easing symptoms associated with these conditions, often applied in a regimen alongside rest and physical therapy. Carisol is applicable within clinical settings that involve acute or disruptive symptom patterns, often used when groups of symptoms appear suddenly.

It is used for managing symptoms of increased muscle tension, which includes manifestations like involuntary muscle spasm, stiffness, and rigidity. This supportive relief contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities. Carisol is commonly used across conditions presenting with acute episodes, relevant for symptoms that may appear suddenly, such as discomfort from a strain, tension following a sprain, or localized muscle tightness.

“The supportive nature of this medication is used to assist the patient in easing the overall symptom load during the acute phase of an injury.”

Carisol is relevant for easing symptoms that create noticeable physiological strain and is commonly used in settings where short-term symptomatic assistance is important for adult patients and adolescents 16 years of age and older.

Quick Fact: Symptomatic Support for Acute Muscular Manifestations
Therapeutic Context: Short-term, adjunctive support for acute musculoskeletal pain.
Symptom Focus: Easing involuntary muscle spasm, stiffness, and tension.

Eligibility and Restrictions for Use

Who can and cannot use Carisol?

Eligibility for Carisol (Carisoprodol) is determined by official regulatory guidelines, which define specific prohibitions and restrictions.

Contraindicated Populations

Carisol is contraindicated and must not be used by patients who have a history of acute intermittent porphyria or a known hypersensitivity reaction to Carisoprodol or a related carbamate compound, such as Meprobamate.

Population Group Eligibility Status Regulatory Requirement
Adults Approved Use Indicated population for treatment.
Children under 16 Not Recommended Safety and efficacy have not been established.
Older Adults (65+) Conditional Use Caution is advised; safety and effectiveness are not established.

Conditional Use and Restrictions

Official labeling mandates caution for specific patient groups:

  • Organ Impairment: Patients with impaired renal function or impaired hepatic function require special consideration, as the safety and pharmacokinetics have not been evaluated in these populations.
  • Substance Use Risk: For addiction-prone individuals, use is restricted and should be limited to the acute treatment period (up to two to three weeks).
  • Pregnancy and Lactation: Use during pregnancy is restricted to cases where the benefit justifies the risk to the fetus (Category C). It is present in breast milk, requiring caution for nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Carisol (Carisoprodol) has officially documented interaction patterns primarily categorized by its metabolism and central nervous system (CNS) activity.

Documented Interaction Patterns

Type of Interaction Interacting Substances / Official Description
Pharmacodynamic Alcohol and other CNS Depressants (including opioids, benzodiazepines, and tricyclic antidepressants) produce additive sedative effects.
Pharmacokinetic (PK) Metabolism is highly dependent on the CYP2C19 enzyme. Inhibitors (e.g., Omeprazole, Fluvoxamine) are documented to increase Carisoprodol plasma concentrations and reduce levels of the active metabolite, Meprobamate. Inducers (e.g., Rifampin, St. John’s Wort) are documented to decrease Carisoprodol plasma concentrations and increase Meprobamate levels.

Official Restrictions and Considerations

Co-administration with Meprobamate is formally not recommended due to expected additive pharmacologic effects, as Meprobamate is the drug’s active metabolite. The medicine is also strictly contraindicated in patients with a history of hypersensitivity to any carbamate derivative. A significant population-specific consideration exists for individuals identified as Poor CYP2C19 Metabolizers, who exhibit substantially higher exposure to Carisoprodol compared to normal metabolizers.

Mechanism of Action

How Carisol Works

Carisol's mechanism of action is defined by a targeted molecular intervention within specific biological signaling pathways. Its primary engagement involves selective interaction with defined receptor or enzyme systems, such as through competitive antagonism or allosteric modulation of enzyme kinetics. This initial binding event modifies the functional activity of these targets, altering the magnitude of subsequent signal transduction cascades.

By modulating these intracellular pathways, Carisol limits the propagation of signaling events within systems characterized by elevated activity. The resultant molecular action culminates in the modulation of overactive or dysregulated physiological responses within defined central or peripheral pathways. This process shifts the overall activity of affected pathways, leading to adjustments in the systemic physiological state that define the drug's activity profile, without reference to therapeutic outcomes.

Dosage and Administration Information

Carisol (Carisoprodol) is administered exclusively through the oral route as a conventional immediate-release tablet, available in 250 mg and 350 mg strengths. The official administration protocol is strictly defined concerning dosage, frequency, duration, and patient population.


Official Administration Regimen

Feature Guideline
Dosing Range The standard single adult dose is 250 mg to 350 mg.
Frequency and Limit The tablet is taken three times a day and at bedtime, totaling four doses daily, with a maximum daily limit of 1400 mg.
Duration of Use Use is limited to short periods, specifically up to two or three weeks.
Contextual Use The medication is designed to be used as an adjunct alongside rest and physical therapy.

Procedural Details and Adjustments

The tablet may be taken with or without food for convenience during the daily schedule. If a dose is missed, it is advised to skip the missed dose if it is nearly time for the next scheduled administration; doses should never be doubled. Carisol is authorized for use only in patients who are 16 years of age and older.

Furthermore, administration requires caution in patients with documented hepatic (liver) or renal (kidney) impairment, as the clearance of the drug may be affected. The overall protocol imposes a time-bound constraint and a maximum daily dosage, clearly defining the structured approach for its use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Carisol

Evidence for Use in Acute Musculoskeletal Spasm

The primary research for Carisol (Carisoprodol) has focused on research exploring the use of Carisol as an additional approach used in research exploring how symptoms change over time for acute, painful muscle spasm, particularly in the lower back. This research has relied mostly on short-term, randomized controlled trials (RCTs). These studies compared Carisol to an inactive substance (placebo) and were applied in research contexts involving fluctuating or unstable symptoms in adult patients who were experiencing the sudden onset of back pain. Outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level were the focus of monitoring in these trials.

These studies monitored symptoms during periods of increased symptom activity and reported how symptoms evolved in the observed populations, such as measurements of changes in patient-reported backache severity. Some findings describe patterns observed in the studies regarding measured differences in disability and functional scores between treatment groups. Overall, systematic reviews of this research contribute to the broader evidence landscape, where the evidence was described as having a moderate level of certainty for short-term outcomes related to acute lower back spasm.


Duration of Evidence and Follow-up Periods

Research exploring short-term symptom changes monitored treatment responses over defined time intervals, meaning that the established period of clinical study characterizing its evaluation is limited to approximately seven days to two or three weeks. Studies focusing on episodes where symptoms become more noticeable do not generally extend past this point. Because of this, long-term effects are not fully established, and there is limited information for long-term outcomes.


Evidence in Specific Patient Groups

The research has primarily been conducted using adult patients (ages 18 and older). Data for groups such as those with significant impairment of the kidneys or liver remain insufficient because these patients were often excluded from the core clinical trials. Similarly, specific evidence for pediatric patients (under 16 years of age) has been limited in the research. The results apply only to the populations studied.


Summary of Research Certainty and Limitations

The main research limitations are consistent: follow-up durations were limited to a few weeks, and sample sizes were modest in some foundational trials. The clinical context of chronic pain or spasms has not been well characterized in controlled trials. The evidence base is heavily concentrated on acute lower back spasm, limiting the available research data for other acute musculoskeletal conditions. Overall, research describes what has been studied for short-term periods in specific populations, and what is still uncertain regarding long-term use and use in broader patient groups.

Key Studies & References

  1. Carisoprodol - StatPearls (Source of population exclusion and duration limits)
  2. Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back (RCT/Study Design Example)

Frequently Asked Questions (FAQ)

Common questions about Carisol (FAQ)

Q: What is the main difference between Carisol and [Name of a similar class drug]?

Carisol is classified as a Centrally Acting Skeletal Muscle Relaxant, meaning its action occurs within the central nervous system. Official documents describe that Carisol is metabolized in the liver to form an active substance called Meprobamate, which also contributes to the drug's effects. Other medications in the same class may not share this specific metabolic pathway.


Q: How does Carisol compare to other established treatments in its class?

Official regulatory documents define Carisol by its specific characteristics, including its classification and the fact that it converts to the active substance Meprobamate. Official product information focuses on describing these specific characteristics and approved use.


Q: Are there any common foods or supplements that might interact with Carisol?

Official documents explicitly warn that Carisol's sedative effects can be increased by alcohol. Additionally, the herbal supplement St. John’s Wort is mentioned because it can affect how Carisol is metabolized in the body. No other common foods or non-herbal supplements are specifically listed as having documented interactions.


Q: Does Carisol cause weight gain or weight loss?

Weight gain or weight loss are not listed among the most common adverse reactions reported in clinical trials or in post-marketing experience for Carisol in official regulatory documents. Official product information primarily highlights central nervous system effects like drowsiness and dizziness.


Q: Is Carisol known to affect sleep patterns?

Carisol can affect sleep, as drowsiness (sedation) is one of the most common reported effects. Official documents also note that insomnia (difficulty sleeping) has been reported in post-marketing experience, particularly in the context of dependence or withdrawal.


Q: What happens if I stop taking Carisol suddenly?

Withdrawal symptoms, including effects like insomnia, vomiting, and tremors, have been reported following the abrupt cessation of Carisol, particularly after prolonged use. Dependence has been reported, and use is recommended only for short-term treatment periods.


Q: Can Carisol affect my heart rate or blood pressure?

Yes, post-marketing experience has reported some cardiovascular reactions. These include tachycardia (a fast or increased heart rate) and postural hypotension (a drop in blood pressure that occurs when standing up). These effects are listed as possible adverse reactions.


Q: Are there any long-term side effects associated with Carisol use?

According to regulatory documents, adequate evidence of effectiveness and safety for prolonged use beyond two or three weeks has not been established. Due to risks of abuse and dependence, treatment is limited to short-term use, meaning long-term effects have not been fully characterized in controlled studies.


Q: Is it normal to feel tired or drowsy after starting Carisol?

Drowsiness is one of the most common adverse reactions reported in clinical trials, occurring in a notable percentage of patients, due to the drug's sedative properties. This is an expected effect based on regulatory reporting.


Q: What does 'contraindication' mean regarding Carisol?

A contraindication is an official statement that describes a specific situation or medical condition in which Carisol is officially restricted from use because the potential risk is too high. For Carisol, contraindications include a history of acute intermittent porphyria or a known allergy to carbamate compounds.


Q: Can children or teenagers take Carisol?

Carisol is officially authorized for use only in patients who are 16 years of age and older. The safety and effectiveness of the medication have not been established in children under 16 years of age.


Q: What is the risk classification for Carisol during breastfeeding?

Official information indicates that Carisol and its active metabolite are present in breast milk. Official information includes a caution that infants should be monitored for signs of sedation (sleepiness), as this effect has been reported in breastfed newborns.


Q: Does Carisol have any known interactions with herbal supplements?

The only herbal supplement specifically mentioned in official interaction warnings is St. John’s Wort. This is noted because it can increase the metabolism of Carisol, which may affect the drug’s concentration in the body.


Q: Is it true that Carisol can be used for things other than its main approved use?

Official regulatory documents describe Carisol's approved indication strictly as relief of discomfort associated with acute, painful musculoskeletal conditions. Regulatory information and controlled clinical trials only address this specific, approved use.


Q: What are the major black box warnings for Carisol, if any?

Carisol's official labeling does not contain a Black Box Warning, which is the strongest caution required by the FDA. However, the label does contain serious warnings about sedation, abuse, dependence, withdrawal, and the risk of seizures.


Q: How quickly does Carisol start to work for most people?

According to the official pharmacokinetic data, the time to reach maximum concentration of Carisol in the blood (Tmax) after a single dose is approximately 1.5 to 2 hours. This is the time frame in which the drug is most concentrated in the body.


Q: Does Carisol interact with common over-the-counter pain relievers like ibuprofen?

Official drug interaction information lists warnings for certain CNS depressants and drugs that affect the CYP2C19 enzyme. Common over-the-counter pain relievers, such as ibuprofen, are not specifically listed as having a documented interaction in the official prescribing information.


Q: What should I do if I think I'm having an allergic reaction to Carisol?

If you experience any signs of an allergic reaction, such as a severe skin rash, hives, or swelling of the face, lips, or throat, official patient counseling information advises that these symptoms should result in contact with a healthcare provider as soon as possible.


Q: Is there a generic version of Carisol available?

Yes, Carisol (Carisoprodol) is available both under its brand name and as generic products. Information from official sources confirms the availability of generic formulations.


Q: Does taking Carisol affect the effectiveness of birth control pills?

Official drug interaction information lists warnings for drugs that affect the central nervous system and those that interfere with the CYP2C19 enzyme. Hormonal birth control pills are not specifically listed as having a documented interaction in the official prescribing information.


Q: How long does Carisol stay in the system after the last dose?

Carisol itself has a half-life of approximately 2 hours, meaning half of the drug is eliminated in that time. Its primary active metabolite, Meprobamate, has a longer half-life of approximately 10 hours and remains in the system for an extended period.


Q: Do I need a prescription from a specialist to get Carisol?

Carisol is legally classified as a Schedule IV controlled substance, and official documents indicate that it requires a prescription from a licensed doctor. The specific type of practitioner (e.g., specialist versus general practitioner) is not addressed in the regulatory information.


Q: Does Carisol affect laboratory test results?

Official information indicates that the active metabolite of Carisol is Meprobamate, which is chemically similar to barbiturates. The presence of Meprobamate may affect the results of certain laboratory tests, such as urine drug screenings, by potentially causing a false positive.

How should Carisol be stored and disposed of?

Storage and Disposal Requirements

Carisoprodol (Carisol) must be stored at controlled room temperature, maintaining a range of 20^circ to 25^circC (68^circ to 77^circF). The medication must be protected from excessive heat, moisture, and freezing.

Container and Security

The tablets should be stored in a closed container and kept tightly closed to protect the contents. As a Schedule IV Controlled Substance, Carisol requires secure placement; it must be kept out of the sight and reach of children and stored in a safe location to prevent misuse.

Disposal of Unused Product

Patients are officially instructed to ask a healthcare professional or pharmacist for guidance on the proper method for disposing of any unused or expired Carisoprodol. This ensures disposal adheres to necessary regulatory standards.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Carisol found in:

A-Z Index: